Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Casita Feliz, a nonprofit serving the Latino LGBTQ+ community in Fresno, recently celebrated its one-year anniversary ...

Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

The U.S. District Court for the Northern District of California ordered Lorik Papyan, who pleaded guilty three years ago to one count of unlicensed wholesale distribution of prescription drugs, to pay ...